Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy ...

Genmab has announced that the European Commission (EC) has approved Tivdak (tisotumab vedotin) to treat recurrent or ...

TIVDAK® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic therapy In the global Phase 3 ...

Data from the innovaTV 204 (NCT03438396) pivotal Phase 2 single-arm clinical trial evaluating TIVDAK as monotherapy in patients with previously treated recurrent or metastatic cervical cancer was ...

Genmab (GMAB) announced that the European Commission has granted marketing authorization for TIVDAK, an antibody-drug conjugate, as monotherapy ...